Levosimendan Kalceks

Levosimendan, the active ingredient in Levosimendan Kalceks, is a calcium sensitizer / inodilator presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in adult patients with the aim of improving cardiac output and relieving symptoms of congestion.

GNH USA supplies Levosimendan Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU markets, and reliable cold‑chain logistics for injectable products.

Levosimendan is used in the management of acute decompensated heart failure, a condition characterized by sudden worsening of cardiac function.

Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. Cardiogenic shock: provides inotropic support while reducing afterload. Low cardiac output syndrome after cardiac surgery: helps maintain hemodynamic stability.

Levosimendan may be associated with a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Hypotension: transient drop in blood pressure. - Tachycardia: increased heart rate. - Arrhythmia: occasional ectopic beats. - Flushing: warm sensation and reddening of skin.

Serious or Rare Side Effects: - Severe hypotension: may require intervention. - Ventricular arrhythmias: potentially life‑threatening. - Myocardial ischemia: chest pain or ECG changes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests. - Thrombocytopenia: reduced platelet count.

When using Levosimendan, clinicians should consider several safety aspects.

Renal impairment: monitor renal function and adjust infusion if needed. Hepatic impairment: use with caution in severe liver disease. Hypotension: avoid rapid infusion in patients with low blood pressure. Concurrent vasodilators: increase risk of hypotension. Electrolyte disturbances: correct before administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with other cardiovascular agents, requiring careful management.

Major Interactions (Avoid): - Sodium nitroprusside: additive vasodilation leading to severe hypotension. - Phosphodiesterase inhibitors (e.g., milrinone): risk of excessive inotropy and arrhythmia. - Beta‑blockers: may blunt desired inotropic effect.

Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor blood pressure for additive hypotensive effect. - Diuretics: watch for electrolyte shifts and volume depletion. - Anticoagulants: monitor for bleeding if hypotension occurs.